Takeda is eager to close its Shire deal and take the specialty pharma under its wing, but for now it's highlighting a few strengths in its own business.

India's Glenmark is opening a $100 million plant in North Carolina to make generic drugs.

Biogen and Eisai defend Alzheimer's drug; Taiho and Servier's Lonsurf shows positive gastric cancer data; J&J pays $2.1 billion for Japan's…

India’s Mercury Laboratories intends to boost its exports but an EMA report shows regulators aren't impressed with what the company is doing now.

China fines vaccine scandal-hit Changsheng $1.3 billion; Merck and Samsung bail on a Lantus biosim; Taiho grows VC fund to sixfold.

The FDA, which banned products from a South Korean sterile manufacturer last spring, has now followed up with a warning letter.

The punishment, an amount rarely seen in China, includes confiscation of illegal gains and a fine three times those sales.

India’s Dr. Reddy’s Laboratories says it will unload an API manufacturing plant to the Middle East-based Neopharma.